Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Librexia STROKE phase 3 trial of milvexian after recent ischemic stroke or high-risk transient ischemic attack
MOH_2023-09-04_012908Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Milvexian plus antiplatelet therapy with Placebo plus antiplatelet therapy (2 arms). Primary endpoint: Time to first stroke. Started Aug 2023; status: recruiting.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on MOH_2023-09-04_012908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-04_012908.